A5018595645- Pharmaceutical Practices and Patient Outcomes
- Nursing Roles and Practices
- Pharmaceutical studies and practices
- Psoriasis: Treatment and Pathogenesis
- Rheumatoid Arthritis Research and Therapies
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune and Inflammatory Disorders Research
- Primary Care and Health Outcomes
- Child and Adolescent Health
- Dermatology and Skin Diseases
- Patient Satisfaction in Healthcare
- Health Sciences Research and Education
- Lymphoma Diagnosis and Treatment
- COVID-19 and Mental Health
- COVID-19 and healthcare impacts
- Opioid Use Disorder Treatment
- Spondyloarthritis Studies and Treatments
- Antibiotic Use and Resistance
- Pharmacovigilance and Adverse Drug Reactions
- Systemic Lupus Erythematosus Research
- Asthma and respiratory diseases
- Stress Responses and Cortisol
- Global Health Workforce Issues
- Pregnancy and Medication Impact
- Pharmaceutical industry and healthcare
University of Salford
2018-2025
Marymount University
2016-2025
Federation University
2023
University of Chester
2005-2017
Pacific Environment
2017
International Food Policy Research Institute
2017
NHS Forth Valley
2016
Pfizer (United States)
2010-2013
University of Manchester
2010
Bath Institute for Rheumatic Diseases
2010
<b>Objectives</b> To compare the efficacy over 12 weeks of two different etanercept regimens in treating skin manifestations psoriasis patients who also have psoriatic arthritis and to evaluate safety an additional open label treatment. <b>Design </b>Randomised double blind multicentre outpatient study. <b>Setting</b> 98 facilities Europe, Latin America, Asia Pacific region. <b>Participants </b>752 with both (evaluated by dermatologists) rheumatologists). <b>Interventions</b> During blinded...
The Eysenck Personality Inventory and Hospital Anxiety Depression scale were administered to 80 patients undergoing medical treatment for long standing inflammatory bowel disease: 22 studied before the diagnosis was established 40 with diabetes mellitus served as controls. High neuroticism introversion scores more prevalent in disease than controls (p less 0.05) these characteristics prominent cases. Introversion increased duration of (r = 0.51). uncommon, occurring only active chronic...
Objectives: To compare the effects of etanercept (ETN) 50 mg once weekly plus methotrexate (MTX) versus MTX alone on patient-reported outcomes (PROs) and relationship between remission PRO improvement. Methods: In this double-blind, randomised clinical trial (COMET), PROs included: Health Assessment Questionnaire (HAQ), EuroQoL health status, fatigue pain visual analogue scales, Hospital Anxiety Depression Scale, Medical Outcomes Short-Form-36. Mean changes from baseline were analysed by...
Abstract Objective To evaluate how continuation of and alterations to initial year 1 combination etanercept–methotrexate (MTX) therapy MTX monotherapy regimens affect long‐term remission radiographic progression in early, active rheumatoid arthritis. Methods Subjects were randomized at baseline for the entire 2‐year period; those who completed treatment with or entered 2. The original group either continued (the EM/EM group; n = 111) received etanercept EM/E 2; M/EM 90) M/M 99) Efficacy end...
To determine the prevalence of joint and nail symptoms, impact these symptoms on health-related quality life (HR-QoL), effects etanercept them in patients with moderate-to-severe plaque psoriasis.In CRYSTEL, psoriasis received continuously (n = 357) or as paused therapy 363) for 54 weeks. In post hoc analyses, baseline characteristics after-treatment changes were evaluated pain psoriasis, pooling across treatment groups. Assessments symptom severity HR-QoL included Subject Global Assessment...
To assess patient-reported outcomes (PRO) in patients with moderate-to-severe plaque psoriasis receiving continuous or paused etanercept treatment.In a multicentre European open-label study, one group (n = 352) received therapy: 25 mg subcutaneously (SC) twice weekly (BIW) throughout 54-weeks. The other 359) 50 SC BIW (<or= 12 weeks) until response was adequate by Physician Global Assessment; after returned, retreatment (25 BIW) begun. PRO included the Dermatology Life Quality Index (DLQI),...
The objective of this post hoc analysis was to test the benefits treating very early rheumatoid arthritis (VERA; ≤4 months) using COMET trial data. Treatment response in VERA and (ERA; >4 months 2 years) with combination etanercept+methotrexate (ETN+MTX) or MTX monotherapy compared.Data assessed at week 52 for baseline disease duration effect included remission (disease activity score (DAS)28 <2.6, SDAI ≤3.3, Boolean), low (LDA; DAS28 <3.2), Boolean components radiographic non-progression....
The absorption of macromolecules from the small intestine rats was studied in terms amount peroxidase activity that appeared thoracic duct lymph after a 10 mg dose horseradish had been injected directly into lumen duodenum. When as solution saline no detected lymph. ethyl alcohol included at final concentrations 12.5-16% flow rate increased markedly for an hour or so and during this time An electronmicroscope study duodenal epithelium exposed to alcoholic solutions showed enzyme penetrated...
Moderate/severe psoriasis combined with psoriatic arthritis (PsA) impairs health-related quality of life (QoL). Etanercept, a fully human tumour necrosis factor-α receptor fusion protein, is approved for treatment both diseases.To compare patient-reported health outcomes (PROs) two etanercept regimens in patients moderate/severe and PsA.In this randomized, double-blind, multicenter study, participants received 50 mg twice weekly (BIW; n = 379) or (QW; 373) 12 weeks open-label QW additional...
To assess the efficacy and safety of two etanercept dose regimens for psoriasis treatment.Subjects were ≥18 years old with stable moderate-to-severe plaque psoriasis. Subjects randomised to 50 mg once weekly (QW) or twice (BIW) double-blind 12 weeks, followed by QW open label in all subjects through week 24. Only mild topical corticosteroids permitted on scalp, axillae groin first weeks; medications (corticosteroids potencies, vitamin D analogues combination products) allowed as needed...
It has been suggested that physiological resistance to repeated stress is associated with increased 5-hydroxytryptamine (5-HT) release in the dorsal hippocampus and dysregulation of this neuroadaptation may be implicated psychopathology depression. This study used 5,7-dihydroxytryptamine lesions investigate role 5-HT projections responses putative changes corticosteroid receptor immunoreactivity brain. Repeated exposure elevated open platform (1 h/day) caused regionally selective...
Journal Article Patients with moderate‐to‐severe psoriasis recapture clinical response during re‐treatment etanercept Get access J.‐P. Ortonne, Ortonne University of Nice‐Sophia Antipolis, Archet 11, 151 Route St Antoine de Ginestieŕe, BP 3079, Nice Cedex 3, France Jean‐Paul Ortonne. E‐mail: ortonne@unice.fr Search for other works by this author on: Oxford Academic Google Scholar A. Taïeb, Taïeb Hôpital Saint Andre, Bordeaux, A.D. Ormerod, Ormerod Aberdeen Royal Infirmary, Aberdeen, Scotland...
Abstract Background Impaired sleep in patients with moderate‐to‐severe psoriasis and improvement on therapy has not been widely studied. Objective Quantify baseline aspects of receiving etanercept (ETN) when allowed concomitant topical medications ( PRISTINE study). Methods Patients were randomized to 50 mg ETN once weekly QW / ) or twice (BIW/QW) for weeks 1–12, followed by 13–24; a broad range therapies permitted during 13–24. Sleep impairment was measured the Medical Outcomes Study MOS...
Deborah Robertson provides an overview of recently published articles that may be interest to non-medical prescribers. Should you wish look at any the papers in more detail, a full reference is provided
Deborah Robertson provides an overview of recently published articles that may be interest to non-medical prescribers. Should you wish look at any the papers in more detail, a full reference is provided
Deborah Robertson provides an overview of recently published articles that may be interest to non-medical prescribers. Should you wish look at any the papers in more detail, a full reference is provided
Deborah Robertson provides an overview of recently published articles that may be interest to non-medical prescribers. Should you wish look at any the papers in more detail, a full reference is provided
The National Aeronautics and Space Administration (NASA) Infrared Telescope Facility was used to investigate the collision of comet Shoemaker-Levy 9 with Jupiter from 12 July 7 August 1994. Strong thermal infrared emission lasting several minutes observed after impacts fragments C, G, R. All warmed stratosphere some troposphere up degrees. abundance stratospheric ammonia increased by more than 50 times. Impact-related particles extended a level where atmospheric pressure measured millibars....
Objective: To evaluate the efficacy and safety of continuous paused etanercept regimens in psoriasis patients. Methods: Patients with moderate-to-severe plaque were randomized to receive 25 mg twice weekly or for 54 weeks. The group received 50 no more than 12 weeks until reaching a Physician Global Assessment (PGA) 2 less (mild better), when treatment was paused; upon relapse (PGA ≥ 3), resumed at PGA regained. primary end point mean over weeks, which compared between groups. Secondary...